Entrada Advances Duchenne Drug to 15 mg/kg Cohort

An independent safety committee recommended starting the third dosing cohort of the ELEVATE-45-201 study of ENTR-601-45.

Updated on Nov. 18, 2026 in Diabetes

Vector editorial illustration of three ascending cylindrical forms of increasing height on a flat plinth, set in generous negative space, evoking a stepwise dose escalation.
Entrada Therapeutics said an independent safety committee recommended starting the third dosing cohort at 15 mg/kg in its ELEVATE-45-201 Duchenne study of ENTR-601-45. AI Illustration. Upload story photo >

Entrada Therapeutics said its Independent Data Monitoring Committee recommended initiating Cohort 3 at 15 mg/kg in the ELEVATE-45-201 Phase 1/2 study of ENTR-601-45 for Duchenne muscular dystrophy. The recommendation followed a review of safety and pharmacokinetic data from eight participants enrolled in Cohort 2.

Why it matters

Duchenne muscular dystrophy is a progressive disease, and the study is testing whether higher doses of an exon 45 skipping therapy can produce greater dystrophin production and functional benefit. Advancing to a higher dose after a safety review is a step toward defining the dose that may later be studied further.

The recommended dose of 15 mg/kg is a step up from 10 mg/kg in Cohort 2 and 5 mg/kg in Cohort 1, based on safety and pharmacokinetic data from eight Cohort 2 participants. Whether the higher dose produces additional dystrophin or functional benefit remains unknown until Cohort 2 data is released in the first half of 2027.

The players

Entrada Therapeutics, Inc.

Entrada Therapeutics is a Boston-based biotechnology company developing oligonucleotide-based therapies for neuromuscular and other diseases.

The details

The Data Monitoring Committee reviewed the data per study protocol before recommending Cohort 3 begin at 15 mg/kg. The study is double-blind and placebo-controlled, and enrolls participants aged four to 20 with exon 45 skipping amenable mutations, a group that Entrada estimates is about nine percent of Duchenne patients.

Timeline

  1. November 18, 2026: Entrada announced the Data Monitoring Committee's recommendation to initiate Cohort 3.

  2. First half of 2027: Entrada plans to share Cohort 2 data.

Health Landscape

Exon skipping antisense oligonucleotide therapies have been developed to restore partial dystrophin production in Duchenne patients whose mutations are amenable to specific exon skipping. Entrada's escalation to 15 mg/kg extends that approach by testing whether higher dosing improves dystrophin production beyond earlier dose levels.

For families affected by exon 45 skipping amenable Duchenne mutations, the study offers a clinical trial path for ages four to 20 in the U.K. and EU. The results will not change standard care until data are reported and any further development steps are taken.

The takeaway

Early-stage dose escalation decisions like this one are made on safety and pharmacokinetic data before any efficacy signal is known, so readers should watch for the Cohort 2 results expected in 2027 before drawing conclusions about benefit.

What happens next

Entrada Therapeutics plans to share Cohort 2 data in the first half of 2027.

Further reading

For more on the disease landscape behind this work, explore our Diabetes coverage.

Source note: This article includes information reported by The Manila times.